ReproCell Stock

ReproCell EPS Growth

The EPS Growth of ReproCell (4978.T) as of Sep 4, 2026 is 403.05 %. In the previous year, EPS Growth was 89.88 % — a change of 348.44% (higher).

EPS Growth

403.05 %

YoY

348.44%

Last updated:

EPS Growth of ReproCell is 2026 403.05 % . EPS Growth of ReproCell was 2025 89.88 % . It decreases by 348.44% higher compared to the previous year.

The ReproCell EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
-118.61 JPY
Jan 1, 2019
74.35 JPY
Jan 1, 2020
-62.24 JPY
Jan 1, 2021
20.26 JPY
Jan 1, 2022
33.44 JPY
Jan 1, 2023
52.13 JPY
Jan 1, 2024
89.88 JPY
Jan 1, 2025
403.05 JPY
The ReproCell EPS Growth history
YEAREPS GrowthYoY
403.05 %+348.44%
89.88 %+72.41%
52.13 %+55.91%
33.44 %+65.05%
20.26 %-132.55%
-62.24 %-183.71%
74.35 %-162.68%
-118.61 %-309.44%
56.63 %-118.79%
-301.40 %+56.60%
-192.46 %
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

EPS Growth of ReproCell is 403.05 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth ReproCell since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's ReproCell historically and in real time.

Access this data via the Eulerpool API

Growth — ReproCell

All Key Metrics — ReproCell